Zahra Pakbaz, MDSickle Cell Disease | February 27, 2024
Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs.
View More
Heme Today Staff WritersAnemia | February 26, 2024
This would be the fourth authorized indication for luspatercept in the European Union.
Patrick DalySickle Cell Disease | February 26, 2024
Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel.
Melissa BadamoSickle Cell Disease | February 22, 2024
Exa-cel eliminated RBC transfusions in patients with transfusion-dependent β-thalassemia.
Patrick DalyAnemia | February 22, 2024
HSCT with a matched unrelated or haploidentical donor was a promising alternative in patients with severe aplastic anemia.
Melissa BadamoSickle Cell Disease | February 21, 2024
Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia.
Patrick DalyHematology | February 20, 2024
The US FDA extended the Priority Review period for the BLA for marnetegragene autotemcel in leukocyte adhesion deficiency-I.
Patrick DalySickle Cell Disease | February 20, 2024
The European Commission has approved the Conditional Marketing Authorization for exagamglogene autotemcel.
Patrick DalyAnemia | February 21, 2024
Low hemoglobin and anemia were found to be modifiable risk factors associated with low cognitive function in older patients.
Patrick DalyHemophilia | February 21, 2024
Desmopressin with FVIII during operations was reportedly feasible and safe in patients with nonsevere hemophilia A.
Patrick DalyAnemia | February 14, 2024
C1-inhibitor administration during transfusions did not significantly suppress hemolysis in autoimmune hemolytic anemia.
Patrick DalySickle Cell Disease | February 13, 2024
Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease.
Melissa BadamoVTE | February 12, 2024
Patients with RA had a 57% increased risk of VTE; a 58% increased risk of DVT; and a 57% increased risk of PE.
Patrick DalyDeep Vein Thrombosis | February 9, 2024
Thrombectomy treatment of iliofemoral DVT reduced the incidence of post-thrombotic syndrome compared with anticoagulants.
John Strouse, MD, PhDSickle Cell Disease | February 15, 2024
Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading.
Patrick DalyPNH | February 6, 2024
The majority of newly diagnosed patients with PNH did not receive a PNH-specific therapy at diagnosis.
Patrick DalySickle Cell Disease | February 8, 2024
Dr. Pakbaz, from the University of California Irvine, shared data on the value of a dedicated classical hematology clinic.
Patrick DalyAnemia | February 5, 2024
Iron deficiency anemia was associated with subsequent diagnosis of gastrointestinal cancers, particularly colorectal cancer.
Patrick DalyThalassemia | February 8, 2024
Direct-acting antiviral therapy was safe and effective in pediatric patients with thalassemia who contracted hepatitis C.
Patrick DalyHemophilia | February 14, 2024
Patients with hemophilia A or B had low rates of VTE after total joint replacement despite infrequent thromboprophylaxis use.
Latest News

February 27, 2024